ArticleNeurochemical research2026
Valproate Releases the Latent Differentiation Capacity of Neuroblastoma by Targeting SP1/CDK4 Signaling.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and analysis of endoplasmic reticulum stress-related genes in neuroblastoma and construction of a prognostic gene signature.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Differentiation therapy represents a standard therapeutic regimen for high-risk neuroblastoma (HR-NB), demonstrating significant efficacy in suppressing tumor recurrence and improving patient survival rates. Retinoic acid (RA) remains the sole clinically approved differentiation-inducing agent for HR-NB, yet its therapeutic application is substantially limited by inherent drug resistance. Here, we found that valproate (VPA) exhibited dose-dependent inhibition of tumorigenicity in NB cells SH-SY5Y, SK-N-BE and retinoic acid (RA)-resistant SK-N-AS, along with the induction of G1-phase arrest and extensive neuronal differentiation. Subsequently, the transcriptomic landscape revealed that the impact of VPA on the biological processes of NB cells was predominantly enriched in the cell cycle pathway and Cyclin Dependent Kinase 4 (CDK4) as the most central gene. Additionally, we found that dual treatment with all-trans retinoic acid (ATRA) synergistically promotes NB cell differentiation, specifically in RA-resistant SK-N-AS cells. We therefore identify VPA as a therapeutic approach to dramatically enhance NB differentiation efficacy that could be used in combination with RA to improve patient outcomes, specifically for patients with RA-resistant HR-NB. These investigations will provide novel insights into cell cycle-mediated differentiation reprogramming in HR-NB.
Indexed as
Identifiers
41484768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.